

## Researcher Profile for Webpage

Name:	Keng-Li Lan	Date: (YYYY/MM/DD):	2020/06/08	
Department:	Division of Radiation Oncology	Position:	Chief	
Email:	kllan@vghtpe.gov.tw	Contact #:	2875-7270	
Education:	Ph.D., Pharmacology; University of Michigan, Ann Arbor, MI, United States, M.D., School of Medicine; National Yang-Ming University, Taipei, Taiwan, R.O.C.,			
Experience:	<p>2019- Now, Chief, Division of Radiation Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.</p> <p>- Now, Attending Physician, Division of Radiation Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.</p> <p>- Now, Associate Professor, Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C.</p>			
Research Interests: (Key words)	Lung, Liver, bile duct, and pancreas cancers treatment; molecular biology and immunotherapy research; development of ANT			
Selected Publications (in recent 5 yr):	<p>Shen YA, Lan KL, Chang CH, Lin LT, He CL, Chen PH, Lee TW, Lee YJ, Chuang CM. Intraperitoneal 188Re-Liposome Delivery Switches Ovarian Cancer Metabolism From Glycolysis to Oxidative Phosphorylation and Effectively Controls Ovarian Tumour Growth in Mice. <i>Radiother Oncol</i> 2016 May; 119(2): 282-90. (IF: 4.817; <i>Radiology, Nuclear Medicine &amp; Medical Imaging</i> 10/124; <i>Oncology</i> 39/213)</p> <p>Li JJ, Lan KL, Chang SF, Chen YF, Tsai WC, Chiang PH, Lin MH, Fischer WB, Shih YS, Yen SH, Liu RS, Tsay YG, Wang HE*, Chang CA*. Development and Characterization of the Recombinant Human VEGF-EGF Dual-Targeting Fusion Protein as a Drug Delivery System. <i>Bioconj Chem</i> 2015 Dec; 26(12): 2481-96. (IF: 4.500; <i>Biochemical Research Methods</i> 10/77; <i>Chemistry, Organic</i> 10/59; <i>Chemistry, Multidisciplinary</i> 31/163; <i>Biochemistry &amp; Molecular Biology</i> 64/289)</p> <p>Chang CM, Lan KL, Huang WS, Lee YJ, Lee TW, Chang CH, Chuang CM*. 188Re-Liposome Can Induce Mitochondrial Autophagy and Reverse Drug Resistance for Ovarian Cancer: From Bench Evidence to Preliminary Clinical Proof-of-Concept. <i>Int J Mol Sci</i> 2017 Apr; 18(5): E903. (IF: 3.226; <i>Chemistry, Multidisciplinary</i> 54/166; <i>Biochemistry &amp; Molecular Biology</i> 116/286)</p> <p>Lee WP, Lan KL, Liao SX, Huang YH, Hou MC, Lan KH*. Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus. <i>Am J Chin Med</i> 2018 -; 46(4): 835-52. Epub 2018 May. (IF: 3.120; <i>Integrative &amp; Complementary Medicine</i> 3/27; <i>Medicine, General &amp; Internal</i> 31/155)</p>			

	Wang SJ, Huang WS, Chuang CM, Chang CH, Lee TW, Ting G, Chen MH, Chang PM, Chao TC, Teng HW, Chao Y, Chen YM, Lin TP, Chang YJ, Chen SJ, Huang YR, Lan KL*. A Phase 0 Study of the Pharmacokinetics, Biodistribution, and Dosimetry of 188Re-Liposome in Patients with Metastatic Tumors. EJNMMI Res 2019 May; 9(1): 46. (IF: 2.630; Radiology, Nuclear Medicine & Medical Imaging 44/129)
Names of Lab members:	

\*NOTE: Keep the contents **within maximum of 2 pages.**